Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
diphtheria, tetanus, pertussis & Hib vaccine · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| diphtheria, tetanus, pertussis & Hib vaccine | BIOLOGICAL | - |
Inclusion Criteria: * A male or female between, and including, 90 and 120 days of age at the time of the first vaccination Written informed consent obtained from the parent or guardian of the subject Exclusion Criteria: * subjects with known exposure to diphtheria, tetanus, pertussis and/or Haemo...
Diphtheria, tetanus, pertussis & Hib vaccine is a combination vaccine being studied for use in preventing tetanus, diphtheria, acellular pertussis, and Haemophilus influenzae type b infections. It is currently in Phase 3 clinical development as an investigational vaccine for these infectious diseases.
GSK plc (ticker: GSK) is developing diphtheria, tetanus, pertussis & Hib vaccine. The company is conducting clinical trials to evaluate the vaccine's safety and reactogenicity in infants.
Diphtheria, tetanus, pertussis & Hib vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 3 trial has been completed to assess its safety and reactogenicity.
Diphtheria, tetanus, pertussis & Hib vaccine has one completed Phase 3 clinical trial, NCT00379977, which assessed its safety and reactogenicity when given at 3, 4, and 5 months of age. The trial enrolled 30 healthy infants in China and was not randomized or blinded.
Diphtheria, tetanus, pertussis & Hib vaccine is not FDA approved. It is an investigational vaccine currently in Phase 3 clinical development. The completed trial evaluated safety and reactogenicity, but the vaccine has not yet received regulatory approval.